| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1999;67:1726-1731
© 1999 The Society of Thoracic Surgeons
a First Department of Surgery, Biomedical Research Center, Osaka University Medical School, Osaka, Japan
b Division of Biochemistry, Biomedical Research Center, Osaka University Medical School, Osaka, Japan
c Molecular and Cellular Biological Center, Osaka University Medical School, Osaka, Japan
Accepted for publication December 31, 1998.
Address reprint requests to Dr Sawa, First Department of Surgery, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka, 565-0871, Japan
e-mail: hueda{at}surg1.med.osaka-u.ac.jp
Background. Hepatocyte growth factor (HGF), a ligand for the c-Met receptor tyrosine kinase, plays a role as organotrophic factor for regeneration of various organs. HGF has an angiogenic activity and exhibits a potent antiapoptotic activity in several types of cells. Although HGF and the c-Met/HGF receptor are expressed in the heart, the role of HGF in the heart has remained unknown.
Methods. After we analyzed changes in expression of endogenous HGF and c-Met mRNA levels in the rat left ventricle after myocardial infarction, the human HGF gene in hemagglutinating virus of Japan (HVJ)-liposome was transfected into the normal whole rat heart. Three days after transfection, the heart was subjected to global warm ischemia and subsequent reperfusion, followed by assessment of its cardiac functions.
Results. Both HGF and c-Met/HGF receptor mRNAs were expressed in adult rat heart, and c-Met/HGF receptor mRNA was upregulated in response to myocardial infarction. HGF-transfected heart showed significant increase of human HGF protein level in the heart. Cardiac functions in terms of the left ventricular developed pressure, maximum dp/dt, and pressure rate product in hearts with HGF gene transfection were significantly superior to those in control hearts. In addition, leakage of creatine phosphokinase in the coronary artery effluent in hearts with HGF gene transfection was significantly lower than that in control hearts.
Conclusions. These data indicated that both HGF and c-Met/HGF receptor mRNAs were upregulated in response to myocardial ischemic injury, and that HGF is likely to have a cytoprotective effect on cardiac tissue, presumably through the c-Met/HGF receptor.
This article has been cited by other articles:
|
|
 |
|
  N. A. Gude, G. Emmanuel, W. Wu, C. T. Cottage, K. Fischer, P. Quijada, J. A. Muraski, R. Alvarez, M. Rubio, E. Schaefer, et al. Activation of Notch-Mediated Protective Signaling in the Myocardium Circ. Res., May 9, 2008; 102(9): 1025 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Li, Z. Wang, H. Ran, X. Li, Q. Yuan, Y. Zheng, J. Ren, L. Su, W. Zhang, Q. Li, et al. Experimental Research on Therapeutic Angiogenesis Induced by Hepatocyte Growth Factor Directed by Ultrasound-Targeted Microbubble Destruction in Rats J. Ultrasound Med., March 1, 2008; 27(3): 453 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shirakawa, Y. Sawa, Y. Takewa, E. Tatsumi, Y. Kaneda, Y. Taenaka, and H. Matsuda Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 624 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Morishita, M. Aoki, and T. Ogihara Does gene therapy become pharmacotherapy? Exp Physiol, May 1, 2005; 90(3): 307 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ohmori, S.-i. Takeda, S. Miyoshi, M. Minami, S. Nakane, M. Ohta, Y. Sawa, and H. Matsuda Attenuation of lung injury in allograft rejection using NF-{kappa}B decoy transfection--novel strategy for use in lung transplantation Eur. J. Cardiothorac. Surg., January 1, 2005; 27(1): 23 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.G Melo, M Gnecchi, A.S Pachori, K Wang, and V.J Dzau Gene- and cell-based therapies for cardiovascular diseases: current status and future directions Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E24 - E35. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Kondo, K. Ohmori, A. Oshita, H. Takeuchi, S. Fuke, K. Shinomiya, T. Noma, T. Namba, and M. Kohno Treatment of acute myocardial infarction by hepatocyte growth factor gene transfer: The first demonstration of myocardial transfer of a "functional" gene using ultrasonic microbubble destruction J. Am. Coll. Cardiol., August 4, 2004; 44(3): 644 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ryugo, Y. Sawa, M. Ono, Y. Miyamoto, A. N. Aleshin, and H. Matsuda Pharmacologic preconditioning of JTE-607, a novel cytokine inhibitor, attenuates ischemia-reperfusion injury in the myocardium J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1723 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hisaka, M. Ieda, T. Nakamura, K.-i. Kosai, S. Ogawa, and K. Fukuda Powerful and controllable angiogenesis by using gene-modified cells expressing human hepatocyte growth factor and thymidine kinase J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1915 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. MELO, A. S. PACHORI, D. KONG, M. GNECCHI, K. WANG, R. E. PRATT, and V. J. DZAU Gene and cell-based therapies for heart disease FASEB J, April 1, 2004; 18(6): 648 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J Hausenloy and D. M Yellon New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway Cardiovasc Res, February 15, 2004; 61(3): 448 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Menasche Cell transplantation in myocardium Ann. Thorac. Surg., June 1, 2003; 75(90060): S20 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ahmet, Y. Sawa, T. Yamaguchi, and H. Matsuda Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart Ann. Thorac. Surg., April 1, 2003; 75(4): 1283 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kitta, R. M. Day, Y. Kim, I. Torregroza, T. Evans, and Y. J. Suzuki Hepatocyte Growth Factor Induces GATA-4 Phosphorylation and Cell Survival in Cardiac Muscle Cells J. Biol. Chem., February 7, 2003; 278(7): 4705 - 4712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jin, R. Yang, W. Li, A. K. Ogasawara, R. Schwall, D. A. Eberhard, Z. Zheng, D. Kahn, and N. F. Paoni Early Treatment with Hepatocyte Growth Factor Improves Cardiac Function in Experimental Heart Failure Induced by Myocardial Infarction J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 654 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Funatsu, Y. Sawa, S. Ohtake, T. Takahashi, G. Matsumiya, N. Matsuura, T. Nakamura, and H. Matsuda Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor J. Thorac. Cardiovasc. Surg., December 1, 2002; 124(6): 1099 - 1105. [Abstract] [Full Text]
|
|
|
|
|
|
I. Ahmet, Y. Sawa, K. Iwata, and H. Matsuda Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: A novel gene therapy for cardiomyopathy J. Thorac. Cardiovasc. Surg., November 1, 2002; 124(5): 957 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Taniyama, R. Morishita, M. Aoki, K. Hiraoka, K. Yamasaki, N. Hashiya, K. Matsumoto, T. Nakamura, Y. Kaneda, and T. Ogihara Angiogenesis and Antifibrotic Action by Hepatocyte Growth Factor in Cardiomyopathy Hypertension, July 1, 2002; 40(1): 47 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Miyagawa, Y. Sawa, S. Taketani, N. Kawaguchi, T. Nakamura, N. Matsuura, and H. Matsuda Myocardial Regeneration Therapy for Heart Failure: Hepatocyte Growth Factor Enhances the Effect of Cellular Cardiomyoplasty Circulation, May 28, 2002; 105(21): 2556 - 2561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ueda, T. Nakamura, K. Matsumoto, Y. Sawa, H. Matsuda, and T. Nakamura A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats Cardiovasc Res, July 1, 2001; 51(1): 41 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xin, S. Yang, G. Ingle, C. Zlot, L. Rangell, J. Kowalski, R. Schwall, N. Ferrara, and M. E. Gerritsen Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in Vivo Am. J. Pathol., March 1, 2001; 158(3): 1111 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Haug, A. Schmid-Kotsas, U. Zorn, M. G. Bachem, S. Schuett, A. Gruenert, and E. Rozdzinski Hepatocyte growth factor is upregulated by low-density lipoproteins and inhibits endothelin-1 release Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2865 - H2871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yasuda, Y. Goto, T. Baba, T. Satoh, H. Sumida, S. Miyazaki, and H. Nonogi Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function J. Am. Coll. Cardiol., July 1, 2000; 36(1): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yasuda, T. Noguchi, M. Gohda, T. Arai, N. Tsutsui, T. Matsuda, and H. Nonogi Single Low-Dose Administration of Human Recombinant Hepatocyte Growth Factor Attenuates Intimal Hyperplasia in a Balloon-Injured Rabbit Iliac Artery Model Circulation, May 30, 2000; 101(21): 2546 - 2549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics, December 21, 2001; 7(2): 79 - 94. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
